Manufacturing sterile injectables drugs in Phase I. Expansion to manufacture solid and semi-solid dosage forms in subsequent phases
Business Model:
Manufacturing in low cost environment with emphasis on excellent quality and marketing in remunerative US and European markets with prior marketing arrangements.
Capitalization:
Equity Contribution from Promoters, Loan from Dena Bank (approved) and additional equity from family, friends and acquitances.
Differentiator:
-
- Project already under implements with majot pieces of the puzzle in place.
- Facility construction in-progress
-